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BACKGROUND—Genetic influences may be discerned in families that have multiple affected
members and may manifest as an earlier age of cancer diagnosis. In this study we determine
whether cancers develop at an earlier age in multiplex Familial Barrett’s Esophagus (FBE)
kindreds, defined by 3 or more members affected by Barrett’s esophagus (BE) or esophageal
adenocarcinoma (EAC).
METHODS—Information on BE/EAC risk factors and family history was collected from
probands at eight tertiary care academic hospitals. Age of cancer diagnosis and other risk factors
were compared between non-familial (no affected relatives), duplex (two affected relatives), and
multiplex (three or more affected relatives) FBE kindreds.
RESULTS—The study included 830 non-familial, 274 duplex and 41 multiplex FBE kindreds
with 274, 133 and 43 EAC and 566, 288 and 103 BE cases, respectively. Multivariable mixed
models adjusting for familial correlations showed that multiplex kindreds were associated with a
younger age of cancer diagnosis (p = 0.0186). Median age of cancer diagnosis was significantly
younger in multiplex compared to duplex and non-familial kindreds (57 vs. 62 vs. 63 yrs,
respectively, p = 0.0448). Mean body mass index (BMI) was significantly lower in multiplex
kindreds (p = 0.0033) as was smoking (p < 0.0001), and reported regurgitation (p = 0.0014).
CONCLUSIONS—Members of multiplex FBE kindreds develop EAC at an earlier age compared
to non-familial EAC cases. Multiplex kindreds do not have a higher proportion of common risk
factors for EAC, suggesting that this aggregation might be related to a genetic factor.
IMPACT—These findings indicate that efforts to identify susceptibility genes for BE and EAC
will need to focus on multiplex kindreds.
Keywords
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INTRODUCTION
Increasing age, male gender, white race, chronic gastro-esophageal reflux disease (GERD),
obesity, and smoking are recognized risk factors for Barrett’s esophagus (BE) and
esophageal adenocarcinoma (EAC) -including esophagogastric junctional adenocarcinoma
(EGJAC)-.(1, 2) Consensus guidelines for screening of BE are based on these risk factors.
(3) We and others have also reported the aggregation of BE and EAC in families and this
syndrome has been termed Familial Barrett’s esophagus (FBE).(4, 5) This aggregation
suggests a biological relationship between BE and EAC. Less than 10% of probands with
these diseases are members of FBE kindreds.(6)
Familial aggregation of diseases may be caused by common environmental exposures in
family members, a genetic predisposition to disease, or both. A younger age of disease
diagnosis in families is often an indication that family members share a genetic
susceptibility. Although associated with gastroesophageal reflux, the development of BE
itself is asymptomatic, and therefore the incident age of BE cannot be determined. In a
previous study, we found that the age of EAC diagnosis in FBE kindreds was the same as in
non-familial kindreds.(7) However, a subsequent segregation analysis demonstrated that the
pattern of aggregation of BE and its associated cancers in FBE pedigrees was clearly more
consistent with a complex genetic model than a purely environmental one.(8) For complex
diseases such as BE and cancer, genetic influences such as a younger age of disease onset
may be more evident in pedigrees that have 3 or more affecteds. Thus, we decided to
perform an updated analysis of age of cancer diagnosis concentrating on the small subset of
FBE kindreds with 3 or more family members affected with BE, or EAC. The primary aim
of this study was to compare age of EAC diagnosis and other known risk factors in kindreds
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with 3 or more affected members termed multiplex FBE, kindreds with 2 affected members
termed duplex FBE, and non-familial kindreds.
METHODS
Recruitment
The recruitment methodology for probands with BE, and EAC and their families for this
ongoing prospective multi-center FBE study has been previously described.(4, 6, 9, 10) The
Familial Barrett’s Esophagus Consortium is an ongoing collaboration started in 1998. The
trial, registered at clinicaltrials.gov with the identifier NCT00288119 aims to ultimately
identify putative susceptibility genes for BE and its associated cancers. Individuals with BE,
EAC, or EGJAC have been recruited at 8 tertiary care academic hospitals in the United
States at varying time periods over the past 8 years.(10) Eligible patients were identified in
the endoscopy suite of participating institutions with IRB approval. These include
individuals with newly-identified BE, those undergoing surveillance endoscopy for BE,
patients with newly-identified EAC and patients with known EAC undergoing endoscopy
for palliation or staging. After providing informed consent, subjects are given a self-
administerd FBE questionnaire. Probands, defined as the first known affected member in a
family, have the opportunity to discuss and clarify family history with their relatives before
mailing back the questionnaire. The questionnaire is structured to systematically collect data
on gastro-esophageal reflux symptoms, risk factors for BE and, EAC such as age, gender,
race, gastroesophageal reflux symptoms (patterned on the validated Mayo GERQ) (11), and
self reported obesity measures at 1, 5, and 10 years prior to diagnosis and family history of
BE, EAC, stomach and throat cancer (which may be incorrect ways of reporting esophageal
cancer). Pedigrees are then constructed from the questionnaire. Permission is obtained to
contact eligible relatives, defined as a first-degree relative of a proband (or confirmed
affected relative). Attempts are made to confirm the diagnosis for all family members
reported to have a history of BE or a suspected esophageal cancer. Eligible family members
are invited to participate over the mail, with a second attempt if there is no reply after 1
month.. For relatives who are deceased, the next of kin are asked to complete the
questionnaire, specifically the age of cancer diagnosis. Institutional review boards for human
investigation at each individual hospital participating in the study have approved this
protocol.
Definitions
For probands as well as relatives, the definition of BE required clear documentation of
endoscopic evidence of BE in the tubular esophagus in the endoscopy report, as well as
histological evidence of intestinal metaplasia on surgical pathology report to satisfy study
criteria. Biopsies reported to be obtained from the gastroesophageal junction, an irregular Z-
line, or at the cardia were not considered to be diagnostic of BE. EAC was defined as a mass
predominantly involving the tubular esophagus or the esophagogastric junction with
histological evidence of an adenocarcinoma. A designated single expert gastrointestinal
pathologist reviewed all biopsies from within an institution. For relatives reported with
esophageal cancer or BE, records were requested from outside hospitals.
Kindreds were classified as confirmed FBE when the diagnosis of BE or EAC was
confirmed in the proband and at least one affected relative by review of records. Kindreds
were classified as possible FBE diagnosis when the proband reported affected family
members but medical records on the family member could not be obtained. Multiplex FBE
kindreds were defined as kindreds with confirmation of diagnosis in at least two members of
the kindred plus additional family members who were reported to be affected with BE or
cancer in whom diagnosis was confirmed or suspected. Individuals were classified as having
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non-familial disease if the proband reported no affected family member or the proband
reported an affected family member but the family member did not meet ascertainment
criteria for BE or EAC upon review of medical records. Duplex FBE kindreds were
classified as confirmed affection status in two members of the kindred or confirmed
affection status in one member plus suspected affection status in second member and no
report of affection status in any other members of the kindred. Only individuals with a
confirmed diagnosis where included in the analysis.
Statistical Analysis
We assessed differences in the age of diagnosis and other variables of interest between the
three family groups (non-familial, duplex and multiplex). For this analysis, data was
available o all subjects in the duplex and multiplex kindreds, and the probands in the non-
familial group (as unaffected relatives do not complete the questionnaire). The specific
variables of interest were age at diagnosis, gender, obesity, race, acid regurgitation,
heartburn, smoking and alcohol consumption. Obesity was examined by comparing the BMI
(in kg/m2) calculated 1 year before diagnosis. When comparing the differences by family
type in the proportion of other cancers, all subjects for all family types were used, utilizing
the information reported by the probands from non-familial pedigrees as a control. Fisher’s
exact tests or Chi-square tests were used to compare categorical variables generating 2-sided
p-values and the Wilcoxon test was used to compare average age at diagnosis and body mass
index (BMI) generating two-sided p-values among different family history types (non-
familial, duplex and multiplex). P-values < 0.05 were considered statistically significant. We
also used multivariable mixed linear models to explore the association between age of
diagnosis and family type, allowing for adjustment for familial correlations of EAC.
Statistical Analysis Software (Version 9.2, SAS, Inc., Cary, NC) was used for all analyses.
RESULTS
A total of 1146 kindreds from the same number of probands were included in the study, 830
(72.4%) non-familial kindreds, 275 (23.9%) duplex kindreds and 41 (3.7%) multiplex
kindreds. (Table 1). The cohort included a total of 1397 individuals affected with either BE
or EAC, of which 1146 were probands and 251 were relatives. There were 947 cases of BE,
of these 566 were in the non-familial kindreds, 288 in duplex kindreds and 103 in multiplex
kindreds. A total of 450 cases of EAC are included, 274 were identified in non-familial
kindreds, 133 in duplex kindreds and 43 in multiplex kindreds. Of the affected individuals,
80.8% were male and 19.2% were female, and the racial distribution was 98% white and 2%
other.
Cancer stage
The cancer stage was not significantly different between the different types of kindreds,
although there was an insignificantly higher proportion of stage III cancer (62.5%) and stage
IV cancer (25%) in the multiplex group. (Table 2).
Age at diagnosis
The median age at the time of diagnosis of EAC was 63 years for non-familial cases, 62
years for individuals in duplex kindreds, and 57 years for those in multiplex kindreds
(p=0.0448). (Table 2). Figure 1 shows a composite histogram for the age at the time of
diagnosis by family type, displaying a leftward shift in the age at diagnosis distribution for
multiplex kindreds when compared to the other groups.
Mixed modeling further supported the association between family history and age at
diagnosis of cancer after adjusting for familial correlations and controlling for multiple
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potential confounders (Table 3). This model only includes subjects with a diagnosis of EAC.
Being an individual from a multiplex kindred was associated with a younger age of
diagnosis (p=0.018). A higher body mass index was also associated a younger age of
diagnosis of cancer (p=0.007). All other variables of interest were not significant in this
model. Hence, the final model only included adjustment for BMI and familial correlations
and showed that being a member of a multiplex kindred was still inversely associated
(p=0.0280, Table 3) with the age of diagnosis.
Symptoms and exposures
Information on symptoms and exposures was available for probands with BE or EAC and
affected relatives (Table 4). There was a statistically significant difference in the number of
individuals that had regurgitation, with a rate of 54.6% from multiplex kindreds, 66.25%
from non-familial kindreds and 57% from duplex kindreds (p = 0.0014). There was no
discernable difference by kindred type in the number of subjects that reported heartburn,
with approximately 70% of subjects in all three groups endorsing the symptom.
The proportion of those that reported smoking was higher in the non-familial kindreds
(64.28%) than in the duplex and multiplex kindreds (51.23% and 45.63% respectively; p
<0.0001). In contrast, more individuals reported alcohol consumption in the multiplex
kindreds (91.19%) when compared to the non-familial and duplex kindreds (80.36% and
84.63%, respectively; p=0.0013). The median body mass index (BMI) was 28.24 for non-
familial cases, 27.8 for duplex kindreds and 27.26 for multiplex kindreds (p=0.0033).
Restricting the analysis to only patients diagnosed with cancer, there were no differences by
family type for heartburn, regurgitation, smoking status, alcohol status or BMI.
Other types of cancer
Self-reported cancer information was obtained from probands regarding their relative’s
cancer status via the questionnaire (Table 5). In multiplex kindreds, 13.88% of individuals
reported a cancer other than esophageal, this proportion was 16.5% in the duplex kindreds
and 16.62% in the non-familial cases (p=0.2407). In this latter category, the most common
cancers reported were in the breast, skin, ovary and prostate. Among those with a family
history of esophageal cancer, the most common other types of cancer reported were breast,
lung, skin and prostate. Multiplex kindreds had a statistically significant greater chance of
lung (p=0.0021), bone (p=0.0027) and liver (p=0.0234) cancer as compared to the other
family types.
DISCUSSION
Earlier age of disease onset is generally considered to be an indicator of genetic
susceptibility to disease. In our previous study of a smaller cohort, when we examined age
of cancer diagnosis in our entire FBE and non-familial cohorts, we failed to identify a
difference in age of cancer diagnosis between familial and non-familial cancers.(7)
However, in this study, once we restricted ourselves to investigating the smaller subset of
multiplex FBE kindreds with 3 or more members with BE, EAC, or EGJAC, we discovered
that EAC is diagnosed at a significantly earlier age in these FBE kindreds when compared to
duplex and non-familial kindreds. This finding is supported by mixed modeling accounting
for familial correlations, with a p-value of 0.028. These results, which support a genetic
basis for FBE, at least in multiplex kindreds, are also consistent with our previous
segregation analysis.(8) The results of this study also suggest that individuals who are
members of multiplex FBE pedigree and are candidates for endoscopic screening (3) may be
considered for screening at an earlier age than the general population.
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Multiplex kindreds also differed significantly from duplex and non-familial kindreds in
terms of risk factors associated with BE and EAC. The proportion of individuals reporting
heartburn, which is the most common symptom of GERD, was not different, although
proportion of individuals with regurgitation was lower. Other risk factors such as high BMI
and smoking, which have been positively associated with BE and EAC in previous studies,
were inversely associated with multiplex FBE kindreds, suggesting that familial aggregation
of BE and its associated cancers is not related to a common exposure to these environmental
factors in family members. Absence of other known risk factors in subjects with FBE also
makes it more likely that a currently unrecognized, and possibly genetic, factor is operative
in these subjects.
The definition of BE in this cohort was quite rigorous and excluded intestinal metaplasia
associated with carditis. Conversely, our definition of the FBE trait was broad and included
BE and EAC because evidence suggests that nearly all EAC develop from BE. (12–17) We
followed the recent TNM Classification that now stages EGJAC similar to EAC. (18)
Interestingly, all but one of the cancers in the multiplex FBE kindreds were EAC’s
suggesting that for the purpose of genetic studies it may be prudent to restrict the trait to
rigorously defined BE and EAC. This study also found that cancers in multiplex FBE
kindreds were not diagnosed at an earlier stage and in fact the results suggest that these
cancers may be more advanced at diagnosis. Although we did not have direct data on which
cancers were diagnosed as a result of endoscopic screening or surveillance, this finding
reassures us that the early age of cancer diagnosis in these multiplex kindreds is not related
to awareness of disease and early medical care seeking behavior in these families.
In other complex diseases, genetic predisposition is manifested strongly in families with 3 or
more affected individuals. For example, the risk of pancreatic cancer is not significantly
increased in families with 2 members with pancreatic cancer but is significantly increased in
families with 3 or more members with the disease.(19) Similarly, an individual’s risk for
colon neoplasias is increased depending on the number of relatives with colon adenomas or
colon cancers.(20, 21) Familial cancer syndromes are often also associated with cancers of
other organs. This study did not find an association between FBE and other cancers in
general. There was a significant association between multiplex FBE and lung, bone and liver
cancer, but the number of subjects reporting these cancers in the present study was small.
Also, cancer in these sites is frequently metastatic, and given our inability to perform
complete review of the entire medical records of all subjects, this information could be
inaccurate. Our database is limited to information obtained from family members who
choose to participate and, because of inability to verify their complete medical record, we
have relied on self-reported diagnoses of other cancers. Many family members chose not to
participate, and differential participation due to chance or diminished survival in cancer
sufferers could easily miss an association between FBE and other cancers. However, we
speculate that another reason could be that FBE is caused specifically by genetic variants
that predispose to an injury to the esophagus or the development of intestinal metaplasia
rather than a more general cancer susceptibility gene.
This study should be interpreted within the limitations of the study design. We had tested the
hypothesis that FBE is associated with an earlier age of cancer diagnosis in our previous
study and had not found an effect.(7) By increasing our power with an expanded cohort, we
were able to discern an effect in multiplex kindreds with the familial group definitions
offered in this study. In this re-analysis of these data, the highly significant p-values
showing marked differences between multiplex kindreds and other BE/EAC/EGJAC
kindreds suggest that these differences are not artifactual. Due to the possibility of lead-time
bias, this finding may warrant further replication. The database is missing information on
several variables for a number of study subjects: missing data on deceased relatives with
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cancer could bias our results, especially since some age of cancer diagnosis information was
collected from proxies. It is unlikely that proxy respondents would systematically
misclassify a younger age of cancer diagnosis in multiplex FBE kindreds, as opposed to
duplex or non-familial kindreds. As in previous studies,(6, 7) we used obesity 1 year prior to
diagnosis for analysis, assuming that the majority of weight loss associated with cancer
diagnosis was within the first year prior to diagnosis. Overweight individuals underreport
weight, which could have lead to an underestimation of obesity.(22) As in our previous
study, mulitvariable mixed linear models were used to adjust for familial correlations
because they allow the specification of and accounting for family correlation structure in our
univariable and multivariable models.(7) Although a statistically-significant difference in
BMI was identified, the biological significance of <1 kg/m2 is unknown. It is likely that
individuals in this study without a genetic susceptibility were misclassified as FBE,
especially in the duplex kindreds and others with a genetic susceptibility were misclassified
as non-familial because we had insufficient information on the family or the family size was
small. However, these misclassifcations would only attenuate differences between multiplex
FBE kindreds and non-familial cases. Of course, true differences in age of cancer diagnosis
can only be measured once the genetic variants in multiplex FBE kindreds have been
identified. Finally, the diagnosis of EAC in a family member might precipitate a lower
threshold for evaluation of GERD symptoms, and perhaps an earlier diagnosis of EAC than
might happen in sporadic cases. However, this bias seems less likely given that multiplex
families with an EAC proband did not have a lower mean age of diagnosis than multiplex
families with a BE proband, as might be expected if cancer fear precipitated earlier
diagnosis. Also, as noted above, cancers diagnosed in multiplex families were not of earlier
stage than those diagnosed duplex or non-FBE families.
To summarize, the results of this analysis indicated that EAC is diagnosed at an earlier age
in multiplex FBE kindreds and might be more advanced at time of diagnosis. Along with the
results of our prior segregation analysis,(8) which indicates that FBE is caused by an
incompletely penetrant autosomally dominant genetic variant, the results of the present
study argue strongly for investigations into the genetic basis of FBE. Such investigations
should focus on FBE kindreds with 3 or more members affected with rigorously defined BE
and EAC phenotypes, because these kindreds have the strongest epidemiological evidence
for a genetic basis. The study results also suggest that screening practices may need to be
modified for an earlier age in these multiplex FBE kindreds.
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Overlapping histograms for age at the time of diagnosis, according to family type.
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Table 1
Individuals with BE and esophageal cancer, by family type
Nonfamilial Duplex Multiplex p-value
Probands 830 275 41
Relatives N/A 146 105
Total individuals 830 421 146
BE 556 288 103
Esophageal Cancer 274 133 43
Gender
Men 693/830(83%) 326/421(77%) 110/146(75%) 0.0076^
Women 137/830(17%) 95/421(23%) 36/146(25%)
White Race 803/828(97%) 390/392(99 %) 137/137(100%) 0.0018*
*
Fishers exact test p-value;
^
Chi-square test p-value
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Table 2
Age of diagnosis and cancer stage for individuals with esophageal cancer
Nonfamilial Duplex Multiplex
Average Age at Cancer
Diagnosis 62.9 (n=274) 62.6 (n=133) 57.6 (n=43) 0.0448#
Cancer Stage
I 55/195(28.2%) 13/57(22.8%) 2/16(12.5%) 0.0535*
II 49/195(25.1%) 15/57(26.3%) 0(0%)
III 66/195(33.8%) 19/57(33.3%) 10/16(62.5%)




Fishers exact test p-value;
^
Chi-square test p-value
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Table 3
Multivariable Mixed models for the association between age at diagnosis of esophageal cancer and family
type.
Multivariable model (adjusted for familial correlations) (n=357) p-value
Family type Multiplex vs. others 0.0180








Multivariable model (adjusted for familial correlations, BMI) (n=279) p-value
Family type Multiplex vs. others 0.0280
Duplex vs. others 0.3966













Chak et al. Page 13
Table 4
Symptoms and exposures according to family type (includes affected individuals in the non-familial group and
all individuals in the duplex and multiplex kindreds)
Nonfamilial Duplex Multiplex p-value
BE/EAC/EGJAC
Affected 830 421 146
Unaffected N/A 3071 1065
Total 830 3438 1211
Heartburn Present
Yes 507/724(70.03%) 339/528(64.20%) 178/263(67.68%) 0.2294*
No 211/724(29.14%) 183/528(34.66%) 84/263(31.94%)
Unknown 6/724(0.83%) 6/528(1.14%) 1/263(0.38%)
Regurgitation Present
Yes 475/717(66.25%) 301/525(57.33%) 144/264(54.55%) 0.0014*
No 233/717(32.50%) 216/525(41.14%) 118/264(44.70%)
Unknown 9/717(1.26%) 8/525(1.52%) 2/264(0.76%)
Smoking
Yes 466/725(64.28%) 271/529(51.23%) 120/263(45.63%) 6.3E-8*
No 251/725(34.62%) 253/529(47.83%) 140/263(53.23%)
Unknown 8/725(1.10%) 5/529(0.95%) 3/263(1.14%)
Alcohol
Yes 581/723(80.36%) 446/527(84.63%) 238/261(91.19%) 8.2E-4*
No 126/723(17.43%) 74/527(14.04%) 22/261(8.43%)
Unknown 16/723(2.21%) 7/527(1.33%) 1/261(0.38%)




Fishers exact test p-value;
^
Chi-square test p-value
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